A micro-dissection platform for generating uniform-sized patient-derived tumor organoids (PDOs) for personalized cancer therapy
A micro-dissection platform for generating uniform-sized patient-derived tumor organoids (PDOs) for personalized cancer therapy
批准号:
10697348
负责人:
Sindy Kam-Yan Tang
金额:
$17.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-05 至 2025-08-31
关键词:
AddressAdoptionAntineoplastic AgentsArchitectureB-LymphocytesBenchmarkingBiologicalCancer BiologyCause of DeathCellsClinicalCryopreservationDataDevicesDiffusionDigestionDissectionDrug ScreeningElementsFibroblastsFlow CytometryGenerationsGenomicsGeometryGoalsGrowthImageImmuneImmune checkpoint inhibitorImmunofluorescence ImmunologicImmunotherapyIn SituIschemiaKidneyLeadLungMacrophageMalignant NeoplasmsManualsMeasuresMechanicsMethodsMicrodissectionMicrofabricationModelingNatural Killer CellsNutrientOrganoidsOutcomeOxygenPatientsPenetrationPerformancePharmaceutical PreparationsPhenotypePlayProcessQuantitative Reverse Transcriptase PCRReproducibilityRoleSamplingSiliconSourceSpecimenStandardizationStromal CellsSurgical PathologyT-LymphocyteTechnologyTestingTimeTissue BanksTissuesTumor TissueTumor-Infiltrating LymphocytesValidationVariantWorkbiobankcancer genomecell typecheckpoint inhibitioncytotoxicityexperimental studyhigh-throughput drug screeningin vivoinstrumentationnanofabricationneoplastic cellnovelpatient responsepersonalized cancer therapypersonalized immunotherapypredictive modelingpreservationreconstitutionresponsetumortumor microenvironmenttumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Patient-derived tumor organoids (PDO), involving the ex vivo culture of fresh tumor fragments,
have emerged as promising models for predicting patient drug response for personalized cancer
therapy. PDOs recapitulate the tumor micro-environment (TME), resemble the source tumor
phenotypically and genomically, and are compatible with high-throughput drug screening.
However, the lack of preservation of immune cells in PDOs has been a major roadblock to
modeling immunotherapy. Our team recently demonstrated a new type of PDO that cultures tumor
fragments as a cohesive unit, allowing the in situ preservation of diverse immune cell types
alongside tumor cells without artificial reconstitution. This approach has enabled the modeling of
patient-specific responses to immune checkpoint inhibitors.
One of the first steps in the generation of PDOs is the dissection of patient tumor specimen
into small fragments. Mechanical dissection, instead of enzymatic digestion, is critical in
preserving the in vivo association between tumor cells and endogenous immune and non-immune
elements. The ability to preserve endogenous immune cells, including tumor-infiltrating
lymphocytes (TIL), is particularly important for personalized immunotherapy testing.
However, current mechanical dissection relies primarily on manual mincing of tumor specimen
into small fragments. It results in fragments with a broad size range, and is imprecise and
irreproducible. Fragments that are too large suffer from inadequate nutrient supply, suboptimal
oxygenation and viability, and poor drug penetration. Fragments that are too small are unlikely to
preserve sufficient stromal cells to support PDO growth, and/or endogenous immune cells which
may be present at low concentrations.
As such, there is an unmet need for a better way to generate tumor fragments of controllable
and uniform size, and identify optimal size(s) to increase the reproducibility and yield of viable
PDOs that can preserve the cellular contexture and tumor architecture. This project aims to
address this need by developing a new method to mechanically dissect tumor specimen into
uniform fragments. Performance measures include fragment size uniformity, PDO viability,
preservation of immune cells, and tumor cytotoxicity in response to immunotherapy. Other cutting
methods including manual mincing will be used as benchmarks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An integrated microtechnology platform for spatially resolved mass spectrometry-based proteomics
-
批准号:10564117
-
项目类别:
-
资助金额:$63.98万
-
财政年份:2023
-
负责人:Sindy Kam-Yan Tang
-
依托单位:
Probing basophil function in microfluidic systems for allergic disease diagnosis
-
批准号:10636914
-
项目类别:
-
资助金额:$19.21万
-
财政年份:2021
-
负责人:Sindy Kam-Yan Tang
-
依托单位:
Probing basophil function in microfluidic systems for allergic disease diagnosis
-
批准号:10457438
-
项目类别:
-
资助金额:$19.21万
-
财政年份:2021
-
负责人:Sindy Kam-Yan Tang
-
依托单位:
Probing basophil function in microfluidic systems for allergic disease diagnosis
-
批准号:10302059
-
项目类别:
-
资助金额:$22.07万
-
财政年份:2021
-
负责人:Sindy Kam-Yan Tang
-
依托单位:
海外基金